Enabling adoption – collaboration delivers fully tested proof of concept design and dataset for NIIMBL-BioPhorum Buffer Stock Blending System

newsAug 30, 2022 | News | Phorum : Technology Strategy

NIIMBL-BioPhorum Buffer Stock Blending System

BioPhorum is pleased to share for the first time the full design and dataset from a Proof-of-Concept which has performed beyond expectations, marking a step change in the biomanufacturing industry’s approach to buffer stock preparation.

The publication of the Addendum to the White Paper (2019) alongside a technical article accepted by the PDA, Evaluation of the design, development, and performance of a simplified modular, mass-flow based, on-demand open-sourced buffer manufacturing system means that the long wait for the output from this three-year undertaking is finally over. For the BioPhorum team, it does not end here – to accelerate the adoption of this innovative system, the design and testing dataset is available open source on BioPhorum.com to allow you and your organization to download the data, and test and implement the system. The team is keen to interact with those looking to apply the Buffer Stock Blending System, answer questions, share their experiences, and track implementation.

Through our Proof-of-Concept Program, BioPhorum is committed to democratizing the availability of technology and lowering barriers to adoption by the biopharmaceutical industry – follow this link to access the design and dataset and other material relating to the collaboration, including a short film showing the impact the performance testing had on some of our members.

The preparation and storage of buffers and solutions during the manufacture of therapeutic proteins requires intensive equipment use, cleanroom footprint, labor, and schedule time. This has a significant impact on the cost of manufacturing and can result in process and facility bottlenecks that reduce overall productivity.

To address this issue, BioPhorum’s Buffer Prep Workstream collaborated with the National Institute for Innovation in Biopharmaceutical Manufacturing (NIIMBL) to design and build a Buffer Stock Blending (BSB) System. This has enabled the BioPhorum team to demonstrate the performance of its recipe-based approach to support on-demand automated buffer delivery for biopharmaceutical processes through precise buffer stock solution blending using mass flow control.

The design process was first documented in 2019 in the NIIMBL-BioPhorum Buffer Stock Blending System: A More Advanced Concept for Buffer Manufacturing and An Economic Evaluation of Buffer Preparation Philosophies for the Biopharmaceuticals Industry papers, which can be found on the BioPhorum website.

Construction of the system was completed in 2020 and the skid itself moved from a vendor in Wisconsin to NIIMBL Headquarters in the new University of Delaware building in Newark. Notwithstanding restrictions imposed during the pandemic in 2020, members of the team located on the East Coast of the US executed the Realization Protocol and then performed a Demonstration (range-finding) Study which has been documented in an article accepted for publication by the PDA, evaluating the learnings and outputs of the test phase.

White Paper Addendum
The Addendum contains information relating to the methods and approach, the testing performed, an analysis of the results, and the lessons learned intending this knowledge base, alongside the PDA article and datasets on the BioPhorum website, to reduce barriers to adoption of this new approach and reducing lead times to implementation. This proof of concept is the first of BioPhorum’s targeted efforts to encourage the adoption of new technologies and processes into the industry; further proof of concept initiatives has been initiated by BioPhorum members who want to leverage the value of collaboration to accelerate robust industry consensus solutions to adoption.

The Addendum describes how a team of biomanufacturers, supply partners and engineering partners with funding from NIIMBL and its own contributions in kind, collaborated on the design and completed performance testing that has demonstrated that the system can produce buffer with ‘game changing’ speed and efficiency. Through online and offline testing, the buffer created met the accuracy requirements of the biomanufacturing industry, at speed. The system was also successfully connected to a chromatography skid to demonstrate how the system supports on-demand buffer delivery to a downstream process. In addition to a full account of the project, the Addendum also contains a comprehensive appendix including online pH and conductivity data from the range-finding study and a list of acronyms used in the document.

Performance Tested
The design and dataset documentation including the piping and instrumentation diagram (PID), Test Protocol and comprehensive data and analysis supports the team’s conclusions that the design, which was tested with four different pumps, provides a flexible solution. This has the potential to reduce cleanroom footprint, and labor, and with ‘game-changing’ speed reduce the planning cycle for manufacturing, eliminating the need for large buffer prep and hold areas and reducing the overall facility footprint for buffer preparation. The system is a significantly faster approach to the production of buffer on-demand and as a result, is expected to reduce operating expenditure.

Members of the team are excited by the potential to produce enough buffer to feed six bioreactors with a single skid, instead of one tank one shift, and believe the NIIMBL-BioPhorum Buffer Stock Blending (BSB) System shows significant potential to reshape existing and future biomanufacturing facilities.

The wait to release the documentation open source has meant that conference presentations were focused on the collaboration and the URS/early design.
To raise the profile of the BSB System, the team agreed on a ‘soft’ launch with Rockwell Automation at the Interphex 2021 trade show in October. The BSB System was shipped to the site and exhibited on the Rockwell Automation stand. Team members from Rockwell, Lonza, and NIIMBL attended and presented the results of the collaboration to delegates, which was well received.

Carrie Mason, Associate Director at Lonza Biologics, said the opportunity to present the BSB System at Interphex was highly positive. “Physically displaying the skid was a win, as many comments were around how compact the skid footprint was while delivering such high output. The attention to detail and design skills of the team really were evident as the skid proved extremely easy to demonstrate how user-friendly it is, from the control panel to the locations of the connections. Interphex enabled showcasing that the BSB System is a reality that can be implemented today in facilities, which is a win for all involved.”

“There was much interest from visitors on what the BSB system was, how it helped overcome an industry challenge, and the amazing collaboration it took to achieve it,” said Doan Chau, Global Life Sciences Industry Consultant at Rockwell Automation. “Many people were impressed by how much faster the system could produce buffers, as compared to traditional ways of manufacturing them.”

Doan Chau also observed, “Many vendors were also very impressed with the collaboration and were really interested in how they could become a part of similar initiatives in the future. It means a lot for Rockwell to be a part of a workstream and project that will ‘revolutionize’ how buffers are made in both large- and small-scale drug manufacturing.”

Follow BioPhorum

Related tags

Recent releases


Submit a Comment

Your email address will not be published. Required fields are marked *

Cell & Gene Therapy

Maximizing the impact of the many advanced therapies under development requires that the industry comes together to improve understanding of how to develop, control and manufacture these life changing therapies.

We connect strategic thinkers in drug development and contract manufacturing organizations with the aim of ensuring harmonization and alignment around issues such as potency assays, phase-appropriate guidance for critical quality attributes, operator safety, regulatory guidelines, and C&GT-specific validation issues, as well as working toward resolving the current challenges to commercializing C&GT products. Discover more and learn about the outputs here.

Development Group

The ever-increasing need to reduce product development lead times and the opportunities to exploit innovative technologies in development are two key industry themes that remain at the forefront of our work. The Phorum successfully connects process development organizations and provides a space where subject matter experts can work on issues such as quality by design and process characterization, cell line technologies, and molecule selection. Read some of the outputs and discover how you could benefit by getting involved.

Drug Substance

Accelerating improvement, exploiting opportunities offered by innovation, and identifying best practice approaches across all aspects of the manufacturing process – these are the essential objectives

Data and digital capabilities are at the core of many of these industry challenges. Work in BioPhorum Drug Substance is informed by BioPhorum Technology Strategy, which has summarized our industry’s market drivers and trends. Capacity, flexibility, sustainability and pace all feature as requirements to succeed in a rapidly changing environment.

Find out more about what our members are currently discussing and learn about some of the successful implementations of our output.

Fill Finish

Quality and demonstrating compliance are two priorities of BioPhorum Fill Finish. Representatives of the world’s top sterile filling operations come together to develop solutions to some of the most intractable technical and regulatory challenges.To address these challenges in drug product aseptic filling (‘fill’) and secondary packaging (‘finish’) operations, our community of industry experts is working relentlessly to continually improve the pharmaceutical quality system (PQS). Together they continue to strive towards developing and implementing safe, predictable, lean, and agile processes in drug product operations. Find out more about the Phorum output here. 

Information Technology

IT and digital advances are crucial in responding to the pharmaceutical industry’s challenges around speed, cost, quality, flexibility, and sustainability. Unlocking and realizing the value in the industry’s IT opportunities is the core mission of the IT Phorum. 

The digital manufacturing facility of the future needs to consider technology advances alongside organizational perspectives while maintaining foundational security requirements. All elements must be considered in the long term to deliver systemic change toward the digital factory vision. Our members collaborate in a format that stimulates and supports industry innovation and implementation. 


BioPhorum Regulatory CMC is affording professionals the opportunity to shape their own collaboration program focused on challenges and opportunities across strategy, science, operations, submissions and compliance. Following a discovery program of work with Heads of Regulatory CMC, in which we identified some key topics of collaboration, we are giving you the opportunity to participate and help us to shape the final collaboration program. This will focus on, filing and review, interactions with Health Authorities, and harmonization. Our mission is not just to discuss, but to deliver applicable outputs and publications that will have an impact – learn more about how you can get involved.

Supply Chain to Patient

The pharmaceutical outbound supply chain was built on a blockbuster model and doesn’t fit the needs of the changing pipeline and new modalities currently being developed. The geopolitical challenges of recent years have shown that the outbound supply chain needs to evolve to become more agile, and resilient, and address a more expectant end-user bying on patient-centricity. Industry collaboration can accelerate improvements and transform performance in a way not possible when working independently. This Phorum is founded on the belief that learning from each other and challenging current thinking to re-imagine the supply chain can reduce costs and increase efficiency.

Supply Partner

BioPhorum SP members want the inbound supply chain for the biomanufacturing industry to be recognized as one of the best-understood and managed global supply chains. They intend to be not only a trusted advisory group but also the engine that drives change for the industry. Working together, we aim to achieve supply chain transformation that provides:

  • an enhanced robustness and resilience
  • accelerated capability and capacity to effect technology adoption
  • reduced cost of quality, and
  • industry-wide alignment on operational implementation

There’s an extensive list of Phorum successes and tangible benefits that have been delivered to define industry best practise.


The BioPhorum Sustainability program is jointly designed, governed, and delivered by a membership drawn from licence holders, contract manufacturers, major suppliers and niche suppliers. This dynamic partnership means that we can quickly focus on the areas that have the greatest industry impact, and we can leverage learning from each other and other sectors – the chemical industry and the built environment for example.

BioPhorum’s unique ability to build a strong coalition for change for an entire industry is now being applied to the greatest challenge of our generation. Driven by evident industry needs, Phorum members are working to develop agreed industry benchmarks, establish the ROI of sustainability investments and to increase the efficacy of implementation of members’ sustainability strategies.

Technology Strategy

With a mission to define strategies to accelerate technology transformation and support the adoption of innovative technologies, BioPhorum Technology Strategy evolved from BioPhorum Technology Roadmapping, strives to realize the technology roadmap vision 2.0.

This is being achieved through a multi-stakeholder team of member companies with collective capability and influence who are committed to driving forth industry goals associated with: Speed to market, Quality, Value, Agility and On-Demand Supply and Sustainability.

Building on industry feedback to standardize plasmid release specifications

Plasmids release specifications are critical to the manufacture of many cell and gene therapy (CGT) products, but current regulatory... read more

How to predict, optimize and analyze high-concentration biologic therapeutic formulations

Developing high-dose biologic drugs for subcutaneous injection often requires high-concentration formulations. It also needs to optimize... read more

A media fingerprinting toolbox that comes with a host of benefits

Cell culture media raw materials can contain many chemical substances, each with its own properties. While simple substances can be... read more

Why 100% visual inspection does not mean 100% defect detection

There is a common misunderstanding that 100% visual inspection (VI) of biopharmaceutical products should mean 100% detection of defects.... read more

How to bridge the data integration gap between sponsors and contract organizations

Bringing BioPhorum’s unique perspective to continuous manufacturing in biologics

Continuous manufacturing (CM) has been a goal for the pharmaceutical industry for several years. While small molecule drug substances and... read more

Supply Chain to Patient has launched!

Have your outbound supply chain costs increased? Do you want to leverage data and digital technologies more effectively to reduce... read more

Electronic data exchange – the foundation for an efficient, resilient inbound supply chain

The COVID-19 pandemic, geopolitical unrest, and military action across the world have fundamentally disrupted the assumption and practice... read more

How are you improving your environmental sustainability performance?

Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health.... read more

Adding value for analytical instrument partners

Analytical instrument vendors have been integral to developing and publishing our technology roadmaps and developing product... read more

Introducing MediPhorum

The medical technology (MedTech) industry is a critical and complex sector. As highlighted during the Covid-19 pandemic, the MedTech industry provides a wide array of products and technologies that are vital to the safe and effective provision of care to many. Also, as seen over recent years, there is often the requirement for flexibility in supply, rapid development, and the introduction of new products to keep pace with global public health demands.

Advanced Wound Care and Wound Management

Advanced wound care (AWC) is the medical treatment for wounds that have not healed properly using conventional wound care products such as gauze, bandages, plasters, and wadding.

AWC involves treating chronic or complex wounds using products that are not as easily obtained over the counter. AWC can be divided into three main categories: wound healing, infection prevention, and restoration.

Drug Delivery

Drug delivery products are therapeutic and diagnostic products combining drugs, devices, and/or biological products, which enable safer and more efficient treatment due to careful and precise drug targeting, local administration, and tailored treatment.

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more
BioPhorum Deliverables Report
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, position papers, guidance documents, assessment tools, industry user requirements, study results, and roadmaps produced in the last twelve months.
BioPhorum Downloads
Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.
Case Studies
Welcome to the BioPhorum case studies page, where you can learn how our clients have used our service to discover innovative solutions and save money. Here you can read real-life stories of how various organizations have used our unique data-driven approach to streamline their processes and make the most of their resources. Whether you're looking for inspiration or want to learn more about the potential benefits of our service, you'll find it here.
Webinars and podcasts
Welcome to BioPhorum Connect, the podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, this podcast brings you the insights and perspectives of experts from around the world. We'll discuss all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. So, join us on our journey as we explore the world of biopharmaceuticals and learn from the perspectives of those at the forefront of the industry.
Share This